Industry News
US healthcare workers lag in flu vaccines: study
Health officials lecture Americans every year on the importance of getting an influenza vaccine but it seems they are not even able to get a majority of their colleagues to do so. [ + ]
WA researchers develop new MRI method
Researchers at the University of Western Australia have developed a novel method for detecting iron overload diseases using magnetic resonance imaging (MRI). [ + ]
Bionomics, WEHI team on drug discovery
After announcing a $6m capital raising yesterday, Adelaide epilepsy specialist company Bionomics Limited (ASX:BNO, US OTC: BMICY) has wasted no time mounting a project to identify new drugs to treat inherited epilepsy and anxiety disorders. [ + ]
Antisense moves into development with growth hormone compound
Antisense Therapeutics (ASX:ANP) has advanced its acromegaly project from research to development after seeing efficacy in animal studies for its antisense compound ATL1103, which targets the growth hormone receptor. [ + ]
Deakin University launches measurement of energy efficiency.
The first mobile facility in the world to measure the energy efficiency of buildings and houses on-site will be launched by Deakin University
[ + ]GM deliberation leaks worry gene advisory chairman
The chair of the NSW Agricultural Advisory Council on Gene Technology, Prof Tim Reeves, has expressed concern that anti-GM representatives on the council have breached its confidentiality code by claiming that the council had already decided to recommend a large-scale trial planting of genetically modified canola in NSW. [ + ]
Ethics, research needs must be balanced: Cotton
An Australian geneticist has called for better balancing of ethical concerns with researchers' needs when it comes to developing guidelines for the collection of human genetic and genomic information into databases for research purposes. [ + ]
Bionomics raises $6m for drug development
Adelaide-based epilepsy specialist Bionomics has raised AUD$6 million in additional capital to fast-track its drug-discovery for new drugs to treat epilepsy and anxiety disorders. [ + ]
Carbon Economy for Northern Australia
Australia's tropical savannas cover two million square kilometres and are largely uncleared. They account for about a third of Australia's land-based carbon stores and have the potential to store even more.
[ + ]Peptech boosts Domantis investment
Sydney biotech company Peptech (ASX:PTD) is lifting its investment in leading UK domain antibody therapeutics developer Domantis by the equivalent of £6.2 million (AUD$15 million) this year to remain Domantis' major investor. [ + ]
New partnership to advance photonics research
A partnership between Swinburne TAFE’s Centre for New Manufacturing and UK-based nanotechnology company Melles Griot will see Swinburne gain cutting-edge nano-positioning equipment that will be a vital tool for researchers in a variety of fields.
[ + ]AustCancer reveals Nasdaq strategy
Australian Cancer Technologies (ASX:ACU) has announced plans to pursue listing on the US Nasdaq exchange, through the American Depositary Receipts (ADR) program. [ + ]
Florey researchers reveal Huntington's secrets
Neuroscience researchers have found evidence that environmental factors play a major role in accelerating or delaying the onset and progression of the lethal brain disorder Huntington's disease in a mouse model. [ + ]
Antisense cheered by Biogen Idec MS drug news
Melbourne company Antisense Therapeutics (ASX:ANP) has been cheered by news this week that Biogen Idec will file early for approval of its monoclonal antibody-based drug for multiple sclerosis. [ + ]
Grant to boost Prana's Alzheimer's project
Melbourne drug-development company Prana Biotechnology (ASX:PBT) will turn up the wick on development of its second-generation drug candidate for Alzheimer's disease PBT-2, after receiving a $1.35 million federal government R&D Start grant. [ + ]
